|Rev $0|Net Loss $3.8M
Equillium, Inc. is a clinical-stage biotechnology company developing novel therapeutics to treat severe autoimmune and inflammatory disorders.
For the full year 2025, Equillium recognized $0 in revenue, compared to $41.1 million in the previous year. The net loss per basic and diluted share (EPS) for the full year 2025 was $(0.39). For the fourth quarter of 2025, revenue was $0, and EPS was $(0.04).
As of December 31, 2025, the company’s cash, cash equivalents, and short-term investments totaled $30.3 million. Including a recently completed $35 million financing, Equillium expects its current balance to successfully fund operations into 2029.
A detailed analysis of Equillium, Inc.’s quarter follows shortly on AlphaStreet.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.